CLINICAL_TRIALS
trial_result
· 2017-06-20
Clinical Trial Update: A Repeat Dose Positron Emission Tomography Study With GSK1144814 [Phase 1]
Summary
A completed Phase 1 repeat-dose PET imaging study evaluating GSK1144814 in schizophrenia.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: GlaxoSmithKline | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED